Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 31

Sales by Activity: AB Science

Fiscal Period: December 2021 (EUR) 2022 (EUR) 2023 (EUR) 2024 (EUR) 2025 (EUR)

Pharmaceuticals

1.61M 958K 970K 1.07M 1.17M

Geographical breakdown of sales: AB Science

Fiscal Period: December 2021 (EUR) 2022 (EUR) 2023 (EUR) 2024 (EUR) 2025 (EUR)

Europe

- - - - 955K

outside Europe

- - - - 219K

Executive Committee: AB Science

Manager TitleAgeSince
Chief Executive Officer - 07/07/2026
Director of Finance/CFO - 20/11/2009
Chief Tech/Sci/R&D Officer - 01/04/2018
Corporate Officer/Principal - -

Composition of the Board of Directors: AB Science

Director TitleAgeSince
Chairman - 11/07/2001
Director/Board Member - 20/09/2011
Director/Board Member 64 27/06/2021
Director/Board Member 68 27/06/2021
Director/Board Member - 27/06/2021
Chairman - 07/07/2026

Shareholders: AB Science

NameStocks%Valuation
UBS Wealth Management SGIIC SA
0.004443 %
3,100 0.004443 % 3 137 €
NameStocks%Valuation
Friedland Gestion SAS
5.198 %
85,471 5.198 % 32 638 €
NameStocks%Valuation
Friedland Gestion SAS
4.167 %
64,103 4.167 % 20 081 €

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com
address AB Science(AB)

Specialty & Advanced Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
+1.88%+5.87%-63.45%-86.54% 48.92M
+0.68%-0.06%+67.68%+22.82% 321B
+0.21%+2.87%+29.78%-10.42% 71.5B
-1.27%+0.57%+37.39%+91.79% 9.88B
-3.60%-1.52%-0.43%-5.11% 8.7B
+1.80%-0.88%-20.84%-3.30% 4.25B
-0.68%+2.94%-38.65%+11.36% 3.86B
+3.08%-5.35%-9.43%+0.75% 3.47B
-2.19%-3.35%+27.21%+45.49% 2.65B
+0.85%+5.41%-3.94%-4.52% 2.23B
Average +0.09%+1.83%+2.53%+6.23% 42.72B
Weighted average by Cap. +0.54%+4.48%+56.14%+17.73%